Aelis Farma discloses share buyback program details

Aelis Farma (Euronext Paris: AELIS), a clinical-stage biopharmaceutical company, has made available the description of its share buyback program, following authorization granted at the company's Annual General Meeting on June 3, 2026.

The buyback program was authorized under the 12th resolution of the Combined General Meeting, pursuant to Article L. 22-10-62 of the French Commercial Code. The Board of Directors was granted powers to implement the program, with the ability to subdelegate in accordance with applicable law.

In accordance with Article 241-3 of the General Regulation of the Autorité des Marchés Financiers (AMF), the program description is included in the company's Universal Registration Document, filed with the AMF on April 23, 2026, under reference number D.26-0284.

You May Also Be Interested In

• AMTD group discloses share repurchase totals, plans to expand buybacks
• Havas repurchases 5,000 shares under €50M buyback program
• Gelum Resources closes $4.3M private placement, hires geophysics firm